<DOC>
	<DOC>NCT00728416</DOC>
	<brief_summary>This study seeks to prospectively demonstrate that Nasonex is better than placebo in relieving nasal congestion in patients with seasonal allergic rhinitis.</brief_summary>
	<brief_title>Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05583)</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>A subject must be 12 years of age or older, of either sex, and of any race. A subject must have at least a 2year history of SAR which exacerbates during the study season. A subject must have a positive skin prick test response to an appropriate seasonal allergen at Visit 1. A subject must be clinically symptomatic at the Screening and Baseline Visits. A subject with a history of severe local reaction(s) or anaphylaxis to skin testing. A subject who has had an upper respiratory tract or sinus infection that required antibiotic therapy without at least a 14day washout prior to the Screening Visit, or who has had a viral upper respiratory infection within 7 days prior to the Screening Visit. A subject who has used any drug in an investigational protocol in the 30 days prior to the Screening Visit. A subject who is participating in any other clinical study. A subject who is part of the staff personnel directly involved with this study. A subject who is a family member (parent, spouse, or sibling) of the investigational study staff. A female subject who is breastfeeding, pregnant, or intends to become pregnant. A subject previously randomized into this study. A subject who has a family member (parent, spouse, or sibling) currently enrolled in this study.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>